Faeth Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

4Oct. 27, 2026, 4:17 p.m. ETView on SEC.gov
8-KOct. 27, 2026, 7:33 a.m. ETView on SEC.gov
Departure/appointment of directors or officers
AI summary, unreviewedFaeth Therapeutics Expands Board to Seven, Appoints Oncology Development Executive Adam Schayowitz as Class III Director
8-KSept. 17, 2026, 4:15 p.m. ETView on SEC.gov
Departure/appointment of directors or officers
4Sept. 15, 2026, 4:58 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 4:22 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 4:15 p.m. ETView on SEC.gov
SCHEDULE 13GAug. 14, 2026, 4:15 p.m. ETView on SEC.gov
SCHEDULE 13G/AAug. 14, 2026, 12 p.m. ETView on SEC.gov
8-KAug. 4, 2026, 7:40 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
10-QAug. 4, 2026, 7:40 a.m. ETView on SEC.gov